Anavex Life Sciences Corp (AVXL)

[Investor2014]

Finally got to listen to the CC and especially the analysts Q&As.

Glad to hear Anavex will get gut microbiome baselined data from the PDD study as patients move into the voluntary open label extension. Then it will be clearer whether Blarcarmesine in fact does affect microbiome diversity increasing the two bacteria families that appear to be associated with better drug response. Whole body homeostasis - Wow! as Tom Bishop expressed it, that would be quite something if it turns out to be correct.

More clarity on the Rett studies in that 6 patients took part in an intensive PK/PD study prior to the dosing of the 15 cohort. These 6 were the subject of the recent DSMB review and join the 15 to make 21 patients in total for the US Rett study that then align to the Avatar study effectively giving us a 51 patient cohort. Also learned that most of the patients enrolled so far are closer to age 18. Topline data readout expected end this year, but not sure if only for the US study or perhaps also AVATAR.

The open label voluntary extension for Rett has the first patient on board. This extension was at first set to be 12 weeks, but will carry on effectively indefinitely (or read until approval).

The Tom Bishop wow may help SP in the coming days...